Cellectar Biosciences INC NEW Stock Prediction
AI-powered sentiment analysis and prediction trends for CLRB, updated each market day.
CLRB AI Sentiment
AI sees no strong directional signal for Cellectar Biosciences INC NEW stock over the next 10 market days.
Prediction date: Sept. 23, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Cellectar Biosciences INC NEW
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Sector
Exchange
Market Cap
$22,685,059
Cap Tier
Employees
11
Headquarters
FLORHAM PARK, NJ
Listed Since
April 19, 2005
Website
CLRB Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CLRB Volatility
Cellectar Biosciences INC NEW has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
